Trial Profile

A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Dec 2024 According to a Lundbeck A/S media release, the company has acquired Longboard Pharmaceuticals and it is now a wholly owned subsidiary of Lundbeck.
26 Aug 2024 According to a Longboard Pharmaceuticals media release, data from the study will be presented at the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress which is taking place in Rome, Italy from September 7-11, 2024.
12 Oct 2023 Results (n=20) Study of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma & CSF Pharmacokinetics & QEEG Changes Reflecting Receptor Engagement presented at the 2023 American College of Clinical Pharmacology Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com